



MAR 24 2006

<b>TRANSMITTAL FORM</b> <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/671,816	
	Filing Date	9/25/2003	
	First Named Inventor	Wong	
	Group Art Unit	1615	
	Examiner Name	Hagopian, C.S.	
Total Number of Pages in This Submission	12	Attorney Docket Number	D-3139CON1

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Stout, Uxa, Buyan & Mullins, LLP		
Signature			
Printed Name	Frank J. Uxa		
Date	3/24/06	Reg. No.	25,612

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO at fax number 571-273-8300, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Janet E. McGhee	Date	3/24/06

The information contained in this facsimile message is privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service.

Appl. No. 10/671,816  
Reply to Office Action of January 12, 2006

RECEIVED  
CENTRAL FAX CENTER  
MAR 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/671,816 Confirmation No. 6866  
Applicant : WONG et al.  
Filed : September 25, 2003  
Title : IMPLANTS AND METHODS FOR TREATING INFLAMMATION-  
MEDIATED CONDITIONS OF THE EYE  
  
TC/A.U. : 1600/1615  
Examiner : Hagopian, Casey Shea  
  
Docket No. : 17656 CON1 (OCU); D3139-CON1  
Customer No. : 33197

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being  
facsimile transmitted to the Patent and  
Trademark Office fax number 571-273-8300  
on the date shown below.

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date: March 24, 2006  
Name: Kurt McGee

AMENDMENT

Sir:

In response to the Office Action of January 12, 2006,  
please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims  
which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.